C-suite remuneration across half a dozen leading pharma companies in India inched upward in 2019-2020, with CEOs and managing directors of local firms continuing to draw larger payouts overall versus their counterparts in foreign listed entities.
But with the coronavirus pandemic clouding broader business outlook, pharma, like other industries, is keeping a tight grip on costs....
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?